Related Experiment Video
Updated: Apr 14, 2026
Establishment of Human Epithelial Enteroids and Colonoids from Whole Tissue and Biopsy
Published on: March 6, 2015
Differentiation-inducing factor-3 inhibits intestinal tumor growth in vitro and in vivo
Naoya Kubokura1, Fumi Takahashi-Yanaga2, Masaki Arioka3
1Department of Clinical Pharmacology, Faculty of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan; Department of Medicine and Clinical Science, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Abstract:
Differentiation-inducing factor-1 (DIF-1) produced by Dictyostelium discoideum strongly inhibits the proliferation of various types of cancer cells by suppression of the Wnt/β-catenin signal transduction pathway. In the present study, we examined the effect of differentiation-inducing factor-3 (DIF-3), a monochlorinated metabolite of DIF-1 that is also produced by D. discoideum, on human colon cancer cell lines HCT-116 and DLD-1. DIF-3 strongly inhibited cell proliferation by arresting the cell cycle at the G0/G1 phase. DIF-3 reduced the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of GSK-3β in a time and dose-dependent manner. In addition, DIF-3 suppressed the expression of T-cell factor 7-like 2, a key transcription factor in the Wnt/β-catenin signaling pathway, thereby reducing the mRNA levels of cyclin D1 and c-Myc. Subsequently, we examined the in vivo effects of DIF-3 in Mutyh(-/-) mice with oxidative stress-induced intestinal cancers. Repeated oral administration of DIF-3 markedly reduced the number and size of cancers at a level comparable to that of DIF-1. These data suggest that DIF-3 inhibits intestinal cancer cell proliferation in vitro and in vivo, probably by mechanisms similar to those identified in DIF-1 actions, and that DIF-3 may be a potential novel anti-cancer agent.
Insights
Differentiation-inducing factor-3 (DIF-3) from Dictyostelium discoideum inhibits colon cancer cell growth by halting the cell cycle and reducing key proteins. DIF-3 also showed effectiveness in reducing intestinal tumors in mice.
Area of Science:
- Cell Biology
- Biochemistry
- Cancer Research
Background:
- Differentiation-inducing factor-1 (DIF-1) from Dictyostelium discoideum inhibits cancer cell proliferation via the Wnt/β-catenin pathway.
- DIF-3 is a related metabolite produced by D. discoideum.
Purpose of the Study:
- To investigate the anti-cancer effects of DIF-3 on human colon cancer cell lines (HCT-116 and DLD-1).
- To elucidate the molecular mechanisms underlying DIF-3's anti-proliferative activity.
- To evaluate the in vivo efficacy of DIF-3 in a mouse model of intestinal cancer.
Main Methods:
- Treatment of HCT-116 and DLD-1 cells with DIF-3.
- Cell cycle analysis (G0/G1 arrest).
- Western blotting to assess protein levels (cyclin D1, c-Myc) and GSK-3β activation.
- Quantitative real-time PCR for mRNA analysis.
- In vivo studies using Mutyh(-/-) mice with induced intestinal cancers, treated orally with DIF-3.
Main Results:
- DIF-3 significantly inhibited colon cancer cell proliferation by inducing G0/G1 cell cycle arrest.
- DIF-3 decreased cyclin D1 and c-Myc expression through GSK-3β activation and subsequent protein degradation.
- DIF-3 suppressed T-cell factor 7-like 2, impacting Wnt/β-catenin signaling and reducing cyclin D1 and c-Myc mRNA levels.
- Oral administration of DIF-3 reduced the number and size of intestinal tumors in mice.
Conclusions:
- DIF-3 exhibits potent anti-proliferative effects on colon cancer cells in vitro and in vivo.
- DIF-3 likely functions through mechanisms similar to DIF-1, involving the Wnt/β-catenin pathway.
- DIF-3 represents a potential novel therapeutic agent for intestinal cancer.
Related Concept Videos
01:12Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
02:23Abnormal Proliferation